We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BioDelivery Sciences International Inc | NASDAQ:BDSI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.59 | 5.60 | 5.61 | 0 | 01:00:00 |
The U.S. Patent and Trademark Office (USPTO) has previously upheld the validity of the ‘167 Patent, after BDSI previously brought challenges to the ‘167 patent in four Inter Partes Review (IPR) proceedings. One IPR was denied institution in May 2015, and MonoSol Rx has now asserted most of those claims against BDSI in this action. The three remaining IPR challenges were decided in final written decisions issued by the USPTO on March 24, 2016, wherein the USPTO upheld the validity of the claims in the ‘167 patent. BDSI is currently appealing these decisions to the Federal Circuit. Because the USPTO already denied BDSI’s IPR, BDSI is barred by statute from challenging any of the Asserted Claims of the ‘167 patent in an IPR, and none of the Asserted Claims are subject to BDSI’s appeal.
“Based on the publicly available information in the BELBUCA™ label alone, it is apparent that BDSI infringes all of these claims,” said Keith Kendall, Chief Executive Officer of MonoSol Rx. “Because of the one-year bar, BDSI cannot avoid this case by filing another IPR, and we look forward to litigating the merits of this case.”
About MonoSol Rx MonoSol Rx is a specialty pharmaceutical company utilizing its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, convenience, compliance and pharmacoeconomics of pharmaceutical products. MonoSol Rx's leadership in film drug technology is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com.
Contact MonoSol Rx Jessica Patel jpatel@monosolrx.com The Ruth Group Lee Roth lroth@theruthgroup.com (646) 536-7012
1 Year BioDelivery Sciences Chart |
1 Month BioDelivery Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions